BRPI0910513A2 - usos de pelo menos um polipeptídeo, usos de pelo menos um vetor recombinante, célula apresentadora de antígeno isolada, célula t isolada, método para a indução de imunidade, métodos para a detecção de câncer e reagente para a detecção de câncer - Google Patents

usos de pelo menos um polipeptídeo, usos de pelo menos um vetor recombinante, célula apresentadora de antígeno isolada, célula t isolada, método para a indução de imunidade, métodos para a detecção de câncer e reagente para a detecção de câncer

Info

Publication number
BRPI0910513A2
BRPI0910513A2 BRPI0910513A BRPI0910513A BRPI0910513A2 BR PI0910513 A2 BRPI0910513 A2 BR PI0910513A2 BR PI0910513 A BRPI0910513 A BR PI0910513A BR PI0910513 A BRPI0910513 A BR PI0910513A BR PI0910513 A2 BRPI0910513 A2 BR PI0910513A2
Authority
BR
Brazil
Prior art keywords
detecting cancer
isolated
cell
polypeptide
reagent
Prior art date
Application number
BRPI0910513A
Other languages
English (en)
Inventor
Fumiyoshi Okano
Masaki Shimizu
Takanori Saito
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of BRPI0910513A2 publication Critical patent/BRPI0910513A2/pt
Publication of BRPI0910513B1 publication Critical patent/BRPI0910513B1/pt
Publication of BRPI0910513B8 publication Critical patent/BRPI0910513B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0910513A 2008-07-10 2009-07-10 uso de pelo menos um polipeptídeo, método para a detecção de câncer de mama e leucemia in vitro, e reagente para a detecção de câncer de mama e leucemia BRPI0910513B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008-180548 2008-07-10
JP2008180548 2008-07-10
PCT/JP2009/062574 WO2010005069A1 (ja) 2008-07-10 2009-07-10 免疫誘導剤及び癌の検出方法

Publications (3)

Publication Number Publication Date
BRPI0910513A2 true BRPI0910513A2 (pt) 2015-09-29
BRPI0910513B1 BRPI0910513B1 (pt) 2020-06-16
BRPI0910513B8 BRPI0910513B8 (pt) 2021-05-25

Family

ID=41507179

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910513A BRPI0910513B8 (pt) 2008-07-10 2009-07-10 uso de pelo menos um polipeptídeo, método para a detecção de câncer de mama e leucemia in vitro, e reagente para a detecção de câncer de mama e leucemia

Country Status (16)

Country Link
US (1) US8901082B2 (pt)
EP (1) EP2319533B1 (pt)
JP (1) JP5703562B2 (pt)
KR (1) KR101323192B1 (pt)
CN (1) CN102089001B (pt)
AU (1) AU2009270182B2 (pt)
BR (1) BRPI0910513B8 (pt)
CA (1) CA2730088C (pt)
DK (1) DK2319533T3 (pt)
ES (1) ES2633468T3 (pt)
HU (1) HUE035804T2 (pt)
MX (1) MX2011000116A (pt)
PL (1) PL2319533T3 (pt)
PT (1) PT2319533T (pt)
RU (1) RU2519675C2 (pt)
WO (1) WO2010005069A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2305300E (pt) 2008-07-10 2016-06-16 Toray Industries Composição farmacêutica para o tratamento e prevenção do cancro
US8430043B2 (en) 2010-10-28 2013-04-30 Columbia Insurance Company Methods and devices for controlling a tufting machine for forming tufted carpet
GB201520565D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
JP7087387B2 (ja) 2016-03-28 2022-06-21 東レ株式会社 免疫誘導剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU640397B2 (en) * 1989-08-25 1993-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
WO2001077332A2 (en) * 2000-04-07 2001-10-18 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors
RU2311920C2 (ru) * 2000-09-20 2007-12-10 Корикса Корпорейшн Композиции и способы для лечения и диагностики рака легких
US7261890B2 (en) * 2001-12-21 2007-08-28 Idexx Laboratories, Inc. Methods for using canine immunoglobulin variable domains and caninized antibodies
WO2004024750A2 (en) * 2002-09-13 2004-03-25 Dyax Corporation Cd44-binding ligands
AU2003298786A1 (en) * 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
JPWO2005083074A1 (ja) 2004-03-01 2007-11-22 有限会社金沢大学ティ・エル・オー 腫瘍抗原ペプチド
JP4547197B2 (ja) * 2004-06-30 2010-09-22 公正 安元 癌特異的腫瘍抗原
WO2008034076A2 (en) * 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008141197A1 (en) * 2007-05-10 2008-11-20 Sea Lane Biotechnologies, Llc Chain reaction creating oligomers from repeat units of binding molecules

Also Published As

Publication number Publication date
WO2010005069A1 (ja) 2010-01-14
EP2319533A4 (en) 2012-11-07
DK2319533T3 (en) 2017-07-17
KR101323192B1 (ko) 2013-10-30
RU2011104704A (ru) 2012-08-20
PL2319533T3 (pl) 2017-10-31
US8901082B2 (en) 2014-12-02
HUE035804T2 (en) 2018-05-28
ES2633468T3 (es) 2017-09-21
BRPI0910513B1 (pt) 2020-06-16
CN102089001B (zh) 2015-01-14
EP2319533B1 (en) 2017-05-10
CN102089001A (zh) 2011-06-08
AU2009270182A1 (en) 2010-01-14
EP2319533A1 (en) 2011-05-11
US20110130343A1 (en) 2011-06-02
MX2011000116A (es) 2011-02-25
CA2730088C (en) 2020-04-14
JPWO2010005069A1 (ja) 2012-01-05
JP5703562B2 (ja) 2015-04-22
PT2319533T (pt) 2017-07-20
RU2519675C2 (ru) 2014-06-20
AU2009270182B2 (en) 2015-01-22
CA2730088A1 (en) 2010-01-14
BRPI0910513B8 (pt) 2021-05-25
KR20110019766A (ko) 2011-02-28

Similar Documents

Publication Publication Date Title
BRPI1014253A2 (pt) polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento
BRPI0906060A2 (pt) anticorpos isolados, métodos de preparo de um anticorpo anti-clostridium difficile, composição e método para a detecção da presença de um esporo de clostridium difficile em uma amostra
BR112012004823A2 (pt) composto de ligação, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos pra produzir um polipeptídeo e para intensificar uma resposta imune em um sujeiro humano, composição farmacêutica, e, anticorpo ou fragmento de ligação de antígeno
BRPI0916964A2 (pt) polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo
BR112014012624A2 (pt) anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
BRPI0814781A2 (pt) Proteína, sequência de ácido nucleico, método para a produção de ácido itacônico, vetor, célula hospedeira, e, uso de um ácido cis-aconítico
BR112013018311A2 (pt) sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada.
CR20110544A (es) Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7
BR112013008255A2 (pt) anticorpo isolado ou um fragmento funcional do mesmo, uso de um anticorpo isolado ou de um fragmento funcional do mesmo, composição farmacêutica, polinucleotídeo, vetor, célula transformada, e, método para produzir anticorpo
BR112014002616A2 (pt) método para detectar cãncer pancreático e reagente ou kit para detectar câncer pancreático
BR112013008602A2 (pt) dispositivo imunocromatográfico, método para a determinação de um carreador gênico, método para o diagnóstico, dispositivo para ensaio imunológico, método para a detecção e determinação da presença de uma proteína e kit
BR112012017094A2 (pt) sistema de deteccção para determinar uma primeira sequência de repetição de n símbolos incluída em um primeiro código, método para determinar uma primeira sequência de repetição de n símbolos incluídos em um primeiro código e programa de computador
DK3502125T3 (da) Peptider og fremgangsmåder til detektering af LYME-sygdomsantifstoffer
ITRM20120383A1 (it) Metodo e kit per la rivelazione di anticorpi.
BR112017009728A2 (pt) anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
BR112012016267A2 (pt) método para detectar informações de controle de enlace descendente e dispositivo para detectar informações de controle de enlace descendente
HUE037095T2 (hu) Eljárások és reagensek monoklonális ellenanyagok elõállítására
CR20120371A (es) Antagonistas de pcsk9
BRPI0905076A2 (pt) Polipeptídeo, anticorpo, região variável, cadeia pesada ou cadeia leve, gene, vetor, célula hospedeira, método para produzir o referido polipeptídeo, e composição farmacêutica compreendendo o mesmo
PL2552955T3 (pl) Przeciwciała o zmodyfikowanym powinowactwie do FcRn, które wspomagają klirens antygenu
BR112013029892A2 (pt) polipeptídeo, molécula de ligação a antígeno, diacorpo e uso de uma porção polipeptídica de uma proteína de ligação a soro desimunizada
MX358772B (es) Metodo para detectar cancer.
BR112015011255A2 (pt) polinucleotídeo que codifica um polipeptídeo de fusão, vetor, polipeptídeo de fusão, célula hospedeira, método para determinar a atividade de neurotoxina, uso do polinucleotídeo e kit.
WO2013181576A3 (en) Methods of evaluating and making biologics
DK2579042T3 (da) Fremgangsmåde til at påvise Aß-specifikke antistoffer i en biologisk prøve

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/06/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF